StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3037% below fair value
$1.66−0.05 (-2.92%)

Close on Nov 16, 2026Market cap $13.69MP/E –Yield –

Lipocine r&d expenses

Research and development expenses are spending on new products and technology.

Lipocine's R&D Expenses for the twelve months ending Jun 30, 2026 was $10.19M, up 74.0% year over year. For fiscal 2025 it was $8.58M, up 16.8% from the year before. Over ten years it grew -3.8% a year on average. The highest annual figure on record is $15.48M in fiscal 2014.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.58M+16.8%
FY2024Dec 31, 2024$7.35M-27.7%
FY2023Dec 31, 2023$10.18M+18.9%
FY2022Dec 31, 2022$8.56M+11.6%
FY2021Dec 31, 2021$7.67M-21.4%
FY2020Dec 31, 2020$9.75M+30.5%
FY2019Dec 31, 2019$7.47M+15.5%
FY2018Dec 31, 2018$6.46M-41.3%
FY2017Dec 31, 2017$11.00M+36.3%
FY2016Dec 31, 2016$8.08M-35.8%
FY2015Dec 31, 2015$12.58M-18.7%
FY2014Dec 31, 2014$15.48M+202.2%
FY2013Dec 31, 2013$5.12M+124.6%
FY2012Dec 31, 2012$2.28M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.04M-4.5%
Q1 FY2026Mar 31, 2026$2.76M+160.4%
Q4 FY2025Dec 31, 2025$2.68M+149.6%
Q3 FY2025Sep 30, 2025$2.71M+70.8%
Q2 FY2025Jun 30, 2025$2.14M+14.0%
Q1 FY2025Mar 31, 2025$1.06M-62.3%
Q4 FY2024Dec 31, 2024$1.07M-35.9%
Q3 FY2024Sep 30, 2024$1.59M-44.9%
Q2 FY2024Jun 30, 2024$1.87M-25.5%
Q1 FY2024Mar 31, 2024$2.82M-9.3%
Q4 FY2023Dec 31, 2023$1.67M+0.3%
Q3 FY2023Sep 30, 2023$2.88M+37.1%
Q2 FY2023Jun 30, 2023$2.52M-13.2%
Q1 FY2023Mar 31, 2023$3.11M+64.5%
Q4 FY2022Dec 31, 2022$1.67M-25.9%
Q3 FY2022Sep 30, 2022$2.10M-11.2%
Q2 FY2022Jun 30, 2022$2.90M+97.9%
Q1 FY2022Mar 31, 2022$1.89M+19.4%
Q4 FY2021Dec 31, 2021$2.25M-9.1%
Q3 FY2021Sep 30, 2021$2.37M-4.9%
Q2 FY2021Jun 30, 2021$1.46M-35.4%
Q1 FY2021Mar 31, 2021$1.58M-37.1%
Q4 FY2020Dec 31, 2020$2.48M+34.7%
Q3 FY2020Sep 30, 2020$2.49M+45.2%
Q2 FY2020Jun 30, 2020$2.27M+15.5%
Q1 FY2020Mar 31, 2020$2.51M+28.8%
Q4 FY2019Dec 31, 2019$1.84M-15.6%
Q3 FY2019Sep 30, 2019$1.71M+20.4%
Q2 FY2019Jun 30, 2019$1.96M+32.5%
Q1 FY2019Mar 31, 2019$1.95M+41.5%
Q4 FY2018Dec 31, 2018$2.18M+23.5%
Q3 FY2018Sep 30, 2018$1.42M-30.5%
Q2 FY2018Jun 30, 2018$1.48M-63.9%
Q1 FY2018Mar 31, 2018$1.38M-55.3%
Q4 FY2017Dec 31, 2017$1.77M+33.0%
Q3 FY2017Sep 30, 2017$2.05M+35.8%
Q2 FY2017Jun 30, 2017$4.11M–
Q1 FY2017Mar 31, 2017$3.08M–
Q4 FY2016Dec 31, 2016$1.33M–
Q3 FY2016Sep 30, 2016$1.51M–

More Lipocine figures

See a number that looks wrong?